Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or metastatic Non-small Cell Lung Cancer

Trial Identifier: D516NC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
NCTID:: NCT06350097
Start Date: April 2024
Primary Completion Date: March 2028
Study Completion Date: May 2032
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Kogarah, AU, 2217
AU Westmead, AU, 2145
CN Changchun, CN, 130000
CN Chongqing, CN, 400030
CN Jinan, CN, 250021
CN Jinan, CN, 250117
CN Kunming, CN, 650118
CN Linhai, CN, 318000
CN Shanghai, CN, 200030
DE Berlin, DE, 13125
DE Frankfurt, DE, 60488
DE Immenhausen, DE, 34376
DE Kiel, DE, 24105
DE Köln, DE, 51109
DE München, DE, 81925
KR Seoul, KR, 06351
KR Seoul, KR, 120-752
KR Seoul, KR, 13620
TW Taipei, TW, 10002
TW Taipei City, TW, 106
TW Taoyuan, TW, 333